Cultural Foundation
Author:
MapLight Therapeutics, Inc.
MapLight Therapeutics to Participate in Upcoming Investor Conferences
May 8, 2026
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 1, 2026
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 26, 2026